We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

86 hedge funds and large institutions have $22.2M invested in Galectin Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more capital invested

Capital invested by funds: $12.7M → $22.2M (+$9.49M)

25% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 20

0.06% less ownership

Funds ownership: 16.67% → 16.61% (-0.06%)

8% less funds holding

Funds holding: 93 → 86 (-7)

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

66% less call options, than puts

Call options by funds: $355K | Put options by funds: $1.05M

Holders
86
Holders Change
-7
Holders Change %
-7.53%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
25
Reduced
20
Closed
21
Calls
$355K
Puts
$1.05M
Net Calls
-$691K
Net Calls Change
+$1.12M

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$1.12M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$272K
3
LPL Financial
LPL Financial
California
+$260K
4
Millennium Management
Millennium Management
New York
+$216K
5
VCM
Vivaldi Capital Management
Illinois
+$175K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$783K
2
GWM
Geneos Wealth Management
Colorado
-$639K
3
YIH
Y-Intercept (HK)
Hong Kong
-$287K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$279K
5
AWS
Atria Wealth Solutions
New York
-$227K
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
26
Group One Trading
Illinois
$140K +$99K +66,196 New
SWP
27
Stratos Wealth Partners
Ohio
$128K +$13.8K +9,200 +18%
HKAM
28
Horizon Kinetics Asset Management
New York
$109K -$3.38K -2,258 -4%
SA
29
Sanctuary Advisors
Indiana
$107K -$3.1K -2,074 -4%
SF
30
Synovus Financial
Georgia
$101K – – –
Simplex Trading
31
Simplex Trading
Illinois
$94K +$65.7K +43,915 +5,637%
XT
32
XTX Topco
Cayman Islands
$90.3K +$44.4K +29,699 +227%
William Blair & Company
33
William Blair & Company
Illinois
$79.9K – – –
Wealth Enhancement Advisory Services
34
Wealth Enhancement Advisory Services
Minnesota
$77.4K -$929 -621 -2%
S4W
35
Solutions 4 Wealth
Texas
$76K – – –
Marshall Wace
36
Marshall Wace
United Kingdom
$64.1K +$45.5K +30,400 New
Mariner
37
Mariner
Kansas
$58K +$1.63K +1,092 +4%
Goldman Sachs
38
Goldman Sachs
New York
$55.4K +$23.3K +15,570 +146%
GIA
39
Gladstone Institutional Advisory
Florida
$52K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$52K +$36.5K +24,389 +4,483%
BCMLT
41
Beacon Capital Management LLC (Tennessee)
Tennessee
$50.4K – – –
IA
42
Inspire Advisors
Idaho
$44.5K – – –
CWM
43
Cahaba Wealth Management
Georgia
$44.3K – – –
STA
44
Summit Trail Advisors
New York
$42.2K +$29.9K +20,000 New
SB
45
SIG Brokerage
New York
$41.1K – – –
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$32.9K +$585 +391 +3%
PAS
47
Point72 Asia (Singapore)
Singapore
$30.8K +$21.8K +14,589 New
ACP
48
Argyle Capital Partners
California
$28.2K – – –
Focus Partners Wealth
49
Focus Partners Wealth
Massachusetts
$28.1K -$21 -14 -0.1%
AA
50
Ancora Advisors
Ohio
$27.4K – – –
1
2
3 4 5

GALT Hedge Fund Activity: Q2 2025 in Review

86 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2025, worth a combined $22.2M — up 75% from $12.7M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of GALT and 15 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 25 added.

The largest buyer was Jane Street, opening a new position worth an estimated $1.12M. The largest seller was BlackRock, cutting an estimated $783K.

  • 86 institutional investors held Galectin Therapeutics (GALT) as of Q2 2025, down from 93 in Q1 2025.
  • Funds reported $22.2M of Galectin Therapeutics stock for Q2 2025, up 75% quarter-over-quarter.
  • 15 funds opened new Galectin Therapeutics positions in Q2 2025 and 21 closed out, a net change of -6 holders.
  • The largest Galectin Therapeutics buyer in Q2 2025 was Jane Street, an estimated $1.12M added.
  • The largest Galectin Therapeutics seller in Q2 2025 was BlackRock, an estimated $783K sold.

Based on aggregated 13F filings for Q2 2025.